Lamivudine/Tenofovir Disoproxil Fumarate

拉米夫定/富马酸替诺福韦二吡呋酯

Report date: 2025/03/19 16:22:36

Base Information

Drug NameLamivudine/Tenofovir Disoproxil Fumarate
Drug Alias NameLamivudine and Tenofovir Disoproxil Fumarate替诺福韦二吡呋酯富马酸盐/拉米夫定Tenofovir Disoproxil Fumarate/LamivudineCimduoTemixys
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, ChronicHIV Infections
Global Approved IndicationsHepatitis B, ChronicHIV Infections
Approved Indications in ChinaHepatitis B, ChronicHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2018/02/28
Country/TerritoryUnited StatesMainland China
CombinationsYes LamivudineTenofovir Disoproxil Fumarate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMylan Nv
China Registration ClassN/A

Develop Information

Active CompaniesMylan Laboratories LtdAnhui Biochem Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, ChronicHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR12
Related LinksN/A